Chronic Myeloproliferative Disorders: From Molecular Physiopathology to Clinical Presentation
نویسندگان
چکیده
منابع مشابه
Chronic Myeloproliferative Disorders
JAK2, an acquired mutation of JAK2, is present in a majority of patients with polycythemia vera and to a lesser extent among patients with the other myeloproliferative disorders. We analyzed the effect of JAK2 on the expression of polycythemia rubra vera 1(PRV-1), using an in vitro model. Compared to wild-type JAK2, the presence of JAK2 increased both PRV-1 protein and mRNA levels in murine mye...
متن کاملChronic myeloproliferative disorders.
The Philadelphia chromosome-negative chronic myeloproliferative disorders (CMPD), polycythemia vera (PV), essential thrombocythemia (ET) and chronic idiopathic myelofibrosis (IMF), have overlapping clinical features but exhibit different natural histories and different therapeutic requirements. Phenotypic mimicry amongst these disorders and between them and nonclonal hematopoietic disorders, la...
متن کاملReview Article Molecular Defects in Chronic Myeloproliferative Disorders
With the exception of chronic myeloid leukemia (CML), the molecular defects in chronic myeloproliferative disorders (MPDs) have not been elucidated. This poor molecular understanding may contribute to the poor and frequently inaccurate classification of these diseases. MPDs are characterized by clonal proliferation of differentiated myeloid cells, and their manifestation can overlap with those ...
متن کاملClinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
Molecular markers are helpful in diagnosis, prognosis and management of haematological malignancies. Recently, a single point mutation in the Janus Kinase 2 (JAK2) gene in the Philadelphia-negative myeloproliferative disorders, including polycythemia vera (over 95%), essential thrombocythemia (50%) and primary myelofibrosis (50%) was identified by several groups. This mutation is now considered...
متن کاملClinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond.
The combined use of bone marrow histopathology, biomarkers and clinical features has the potential to diagnose, stage and distinguish early and overt stages of ET, PV and idiopathic myelofibrosis, that has an important impact on prognosis and treatment of MPD patients. As the extension of the PVSG and WHO for ET, PV and agnogenic myeloid metaplasia (AMM), a new set of European clinical and path...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nihon Naika Gakkai Zasshi
سال: 2007
ISSN: 0021-5384,1883-2083
DOI: 10.2169/naika.96.1329